Crossmark Global Holdings Inc. lowered its position in Henry Schein, Inc. (NASDAQ:HSIC – Get Rating) by 52.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,742 shares of the company’s stock after selling 14,286 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Henry Schein were worth $1,018,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in Henry Schein by 1.4% in the first quarter. Vanguard Group Inc. now owns 15,331,533 shares of the company’s stock valued at $1,336,756,000 after purchasing an additional 214,846 shares in the last quarter. Pendal Group Ltd grew its stake in Henry Schein by 26.0% in the third quarter. Pendal Group Ltd now owns 4,414,378 shares of the company’s stock valued at $290,334,000 after purchasing an additional 910,179 shares in the last quarter. Macquarie Group Ltd. grew its stake in Henry Schein by 7.9% in the third quarter. Macquarie Group Ltd. now owns 2,434,865 shares of the company’s stock valued at $159,915,000 after purchasing an additional 178,783 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new stake in shares of Henry Schein during the 2nd quarter worth about $159,204,000. Finally, Fiduciary Management Inc. WI boosted its stake in shares of Henry Schein by 45.5% during the 3rd quarter. Fiduciary Management Inc. WI now owns 1,913,031 shares of the company’s stock worth $125,820,000 after acquiring an additional 597,877 shares in the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.
Insider Buying and Selling at Henry Schein
In other Henry Schein news, Director Kurt P. Kuehn sold 1,909 shares of the company’s stock in a transaction that occurred on Thursday, March 16th. The stock was sold at an average price of $77.46, for a total value of $147,871.14. Following the completion of the transaction, the director now owns 15,675 shares of the company’s stock, valued at approximately $1,214,185.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Henry Schein news, Director Philip A. Laskawy sold 6,405 shares of the company’s stock in a transaction that occurred on Friday, March 3rd. The stock was sold at an average price of $78.74, for a total value of $504,329.70. Following the completion of the transaction, the director now owns 26,239 shares of the company’s stock, valued at approximately $2,066,058.86. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Kurt P. Kuehn sold 1,909 shares of the company’s stock in a transaction that occurred on Thursday, March 16th. The shares were sold at an average price of $77.46, for a total value of $147,871.14. Following the completion of the transaction, the director now directly owns 15,675 shares of the company’s stock, valued at approximately $1,214,185.50. The disclosure for this sale can be found here. Insiders own 1.00% of the company’s stock.
Henry Schein Price Performance
Henry Schein (NASDAQ:HSIC – Get Rating) last posted its quarterly earnings results on Thursday, February 16th. The company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.21 by $0.14. The firm had revenue of $3.37 billion during the quarter, compared to analysts’ expectations of $3.37 billion. Henry Schein had a return on equity of 15.79% and a net margin of 4.25%. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.07 EPS. Research analysts predict that Henry Schein, Inc. will post 5.32 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on the company. UBS Group upped their price target on Henry Schein from $75.00 to $82.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 7th. Barrington Research decreased their price target on Henry Schein from $99.00 to $92.00 and set an “outperform” rating for the company in a research note on Friday, February 17th. Morgan Stanley decreased their price target on Henry Schein from $70.00 to $69.00 and set an “underweight” rating for the company in a research note on Tuesday, February 21st. Piper Sandler upped their price target on Henry Schein from $85.00 to $97.00 and gave the stock an “overweight” rating in a research note on Monday, February 6th. Finally, Credit Suisse Group decreased their price target on Henry Schein from $99.00 to $97.00 and set an “outperform” rating for the company in a research note on Tuesday, February 28th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $85.89.
About Henry Schein
Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins.
Featured Articles
- Get a free copy of the StockNews.com research report on Henry Schein (HSIC)
- MarketBeat Week in Review – 3/27 – 3/31
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
